We’re Making History!

30 years of delivering early intervention orthopedic products that help Restore Active Living for people around the world

Explore some of Anika’s Milestones:

Anika History

2024

Commenced full market release of the Integrity™ Implant System, a regenerative hyaluronic acid-based scaffold for tendon repair, along with its complete arthroscopic instrumentation platform for rotator cuff repair.

Launched the biocomposite X-Twist™ Fixation System suture anchor for rotator cuff and other soft tissue repair.

Launched AIM^™ (Anika Implant Management) Software System, a 3D preoperative planning program compatible with the OVOMotion^® and RevoMotion^® shoulder implant systems.

2023

Received 510(k) clearance then commenced limited market release after performing first surgeries using the Integrity Implant System.

Launched RevoMotion Reverse Shoulder Arthroplasty System, a bone conserving solution for reverse shoulder arthroplasty.

Completed enrollment in Hyalofast^® pivotal Phase III clinical study, a key milestone in its path to achieving US FDA approval.

Tactoset^® received additional FDA 510(k) clearance to be combined with autogenous bone marrow aspirate (BMA).

Commenced full market release of X-Twist Fixation System, a cornerstone product in Anika’s Sports Medicine portfolio.

2022

FDA 510(k) clearance received and first surgeries performed with the X-Twist Fixation System, a highly versatile suture anchor system, and a cornerstone product for Anika’s sports medicine portfolio.

Received the ACE Award for cutting-edge innovation from the American Orthopedic Society for Sports Medicine (AOSSM) for Tactoset Injectable Bone Substitute for hardware augmentation.

First surgeries were performed using the X-Twist Fixation System and limited market release commenced.

Cingal^® successfully achieved its primary endpoint in its third Phase III clinical trial.

2021

WristMotion^® Total Wrist Arthroplasty System launched for the replacement of painful wrist joints.

FDA 510(k) clearance received for Tactoset Injectable Bone Substitute to include a new indication for augmentation of hardware, including suture anchors.

Competed enrollment for US pilot clinical study of Cingal, a combination hyaluronic acid (HA) and fast-acting steroid injection for osteoarthritis knee pain.

Hosted an Investor Day, which detailed Anika’s multi-year strategy and roadmap of becoming a global leader in joint preservation and restoration.

2020

Anika acquired Arthrosurface, a leading, privately-held provider of joint preservation solutions, and Parcus Medical, a leading, privately-held sports medicine company.

Cheryl R. Blanchard, Ph.D., appointed as President and Chief Executive Officer.

FDA 510(k) clearance received for its WristMotion Total Wrist Arthroplasty (TWA) System.

FDA 501(k) clearance received for Actiflip, a button fixation system for biceps tenodesis.

2019

Tactoset was launched in the United States, a surgically delivered therapy for insufficiency fractures.

510(k) clearance received for the company’s first suture anchors comprised of biocomposite material bTCP/PLGA².

FDA clearance received for Synd-EZ Kits for ankle syndesmosis repair².

ATLAS (Anatomic Thumb Ligament Arthroplasty System), a more anatomical and less invasive arthroplasty solution to treat arthritis of the CMC joint (thumb), gained 501(k) clearance².

2018

First surgery performed using the anatomic OVOMotion^® with Inlay Glenoid Total Shoulder Arthroplasty (TSA) implant¹.

Monovisc^® and Orthovisc^® became the #1 prescribed viscosupplement franchise in the United States.

2017

FDA 510(k) clearance received for HA-enhanced Tactoset Injectable Bone Substitute for the treatment of insufficiency fractures.

501(k) clearance received for Slik Knotless Screw-In Suture Anchors and Slik Fix Tenodesis System².

2016

International launch of Cingal, the first HA-based viscosupplement plus steroid combination product for the treatment of osteoarthritis pain.

510(k) clearance received for the GFS Ultimate adjustable suture loop, further expanding the portfolio of graft fixation system (GFS) products².

First surgery performed using the company’s first tissue-based product, the Glenojet^® Allograft System for shoulder glenoid reconstruction¹.

CE Mark approval received for Orthovisc^®-T, a treatment designed to relieve pain and restore function for patients with chronic tennis elbow.

2015

Entered the hand & wrist market with the WristMotion Hemiarthroplasty Implant¹.

A larger 5x5cm Hyalofast^® scaffold to treat large cartilage defects was introduced internationally.

2014

FDA approval and launch of Monovisc, the first non-animal sourced hyaluronic acid single-injection treatment for knee osteoarthritis in the United States.

First surgery performed using the ToeMotion^® Total Toe System, designed to restore mobility and maintain native biomechanics¹.

2013

FDA clearance received for DrawTight, an innovative suture-based anchor for use in both large and small joint repairs².

2012

Orthovisc achieved #1 U.S. market leader position in the multi-injection viscosupplement market.

First procedure performed using NanoFx^®, an improved microfracture solution compared to the standard marrow-based regenerative technique¹.

2011

First surgery performed using the anatomic OVO^® implant for the treatment of glenohumeral osteoarthritis (OA)¹.

2010

Received CE mark certification and launched its first sports medicine soft tissue repair solutions in the European Union².

2009

Acquired technology used in Hyalofast, a one-step cartilage regeneration product, through the strategic acquisition of Fidia Advanced Biopolymers, a leading innovator in hyaluronic acid-based tissue engineered products, based in Abano Terme, Italy.

Hyalofast received CE mark approval and launched internationally.

Received 510(k) clearance for the first PEEK CF (carbon fiber reinforced polyetheretherketone) suture anchors and interference screws used in sports medicine².

First surgery performed using the Arthrosurface Toe HemiCAP^® DF, its third anatomic foot & ankle implant brought to market since entering the foot & ankle space in 2005¹.

First surgery performed using the anatomic PF Wave^® knee implant¹.

First 510(k) clearances received for titanium soft tissue fixation devices².

2008

2007

CE mark approval received for Monovisc in Europe.

Parcus Medical, LLC was founded by partners with extensive orthopedic industry experience².

2004

Obtained FDA approval for and launched Orthovisc in the United States.

First international anatomic joint preservation implant surgeries performed in the knee and shoulder¹.

2003

First anatomic joint preservation implant surgeries performed in the shoulder in the United States¹.

Established a marketing and distribution relationship with Johnson & Johnson to sell Orthovisc in the United States once approved by the FDA.

2001

Arthrosurface was founded and incorporated¹.

1996

Received CE mark approval for and launched Orthovisc internationally, the company’s first HA-based viscosupplement used for the treatment of osteoarthritis pain.

1995

Signed a distribution agreement with Boehringer Ingelheim Vetmedica for its HA-based equine osteoarthritis product, Hyvisc^®, a partnership that has continued to this day.

1992

Anika Therapeutics was incorporated as a spin-off of MedChem Products, Inc.

Signed an agreement with Johnson & Johnson to manufacture and supply its hyaluronic acid-based ophthalmic products, Amvisc^® and Amvisc^® Plus.

Brought to Anika through the acquisition of Arthrosurface, Inc.
Brought to Anika through the acquisition of Parcus Medical LLC